Short Communication: Biological and Genetic Characterization of HIV Type 1 Subtype B and Nonsubtype B Transmitted Viruses: Usefulness for Vaccine Candidate Assessment

Abstract

Due to the extraordinary degree of genetic diversity of HIV-1 and the structural complexity of its envelope glycoproteins, designing an effective vaccine is difficult, requiring the development of viral reagents to assess vaccine-elicited neutralizing antibodies. The aim of this study was to improve on our previously developed panel of HIV-1 strains of different genetic forms, focusing on strains from acute and recently acquired infections as the most representative of the transmitted viruses. HIV-1 primary isolates were expanded in peripheral blood mononuclear cells. Viral stocks of 40 ml each were produced. Syncytium-inducing (SI) phenotype, coreceptor use, and TCID₅₀/ml were determined. Near full-length HIV-1 genomes were amplified by RT-nested PCR in four overlapping segments. Phylogenetic analyses were performed with neighbor-joining trees and bootscanning. Forty-four HIV-1 strains were included in the panel. Twenty-four (54.1%) strains were from early infections (16 acute and 8 recent); of them, 21 (87%) were sexually transmitted. NSI/R5 phenotype was detected in 37 (84.1%) viruses and SI/R5,X4 in another 7 (15.9%). TCID₅₀/ml ranged between 10⁴ and 10^6.6. Twelve different genetic forms constituted this panel: subtypes A1, B, C, F1, and G; circulating recombinant forms CRF02_AG, CRF14_BG, and CRF24_BG; and unique recombinant forms CRF02_AG/A3, BF1, CRF12_BF/B, and DF1G. In conclusion, in this study, we report the development of a comprehensive and well-characterized panel of HIV-1 isolates for assessing neutralization in HIV vaccine research. This panel is available for distribution through the Programme EVA Centre for AIDS Reagents, National Institute for Biological Standard and Control (NIBSC).

Get full access to this article

View all access options for this article.

References

Taylor

, Sobieszczyk

, McCutchan

et al. The challenge of HIV-1 subtype diversity. N Engl J Med, 2008; 358,15:1590–1602.

Woodman

, Williamson

. HIV molecular epidemiology: Transmission and adaptation to human populations. Curr Opin HIV AIDS, 2009; 4,4:247–252.

Brown

, Darden

, Tovanabutra

et al. Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of a candidate vaccines. J Virol, 2005; 79,10:6089–6101.

Fernández-García

, Cuevas

, Muñoz-Nieto

et al. Development of a panel of well-characterized human immunodeficiency virus type 1 isolates from newly diagnosed patients including acute and recent infections. AIDS Res Hum Retroviruses, 2009; 25,1:93–102.

Hollinger

, Bremer

, Myers

et al. Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS Clinical Trials Group. The NIH/NIAID/DAIDS/ACTG Virology Laboratories. J Clin Microbiol, 1992; 30,7:1787–1794.

Björndal

, Deng

, Jansson

et al. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol, 1997; 71,10:7478–7487.

Cecilia

, KewalRamani

, O'Leary

et al. Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage. J Virol, 1998; 72,9:6988–6996.

Japour

, Mayers

, Johnson

et al. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group. Antimicrob Agents Chemother, 1993; 37,5:1095–1101.

Delgado

, Thomson

, Villahermosa

et al. Identification of a newly characterized HIV-1 BG intersubtype circulating recombinant form in Galicia, Spain, which exhibits a pseudotype-like virion structure. J Acquir Immune Defic Syndr, 2002; 29,5:536–543.

10.

Sierra

, Thomson

, Rios

et al. The analysis of near full-length genome sequences of human immunodeficiency virus type 1 BF intersubtype recombinant viruses from Chile, Venezuela and Spain reveals their relationship to diverse lineages of recombinant viruses related to CRF12_BF. Infect Genet Evol, 2005; 5,3:209–217.

11.

Lole

, Bollinger

, Paranjape

et al. Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol, 1999; 73,1:152–160.

12.

Hillis

, Bull

. An empirical test of bootstrapping as a method for assessing confidence in phylogenetic analysis. Syst Biol, 1993; 43,2:182–192.

13.

Fernández-García

, Pérez-Alvarez

, Cuevas

et al. Identification of a new HIV-1 circulating BF intersubtype recombinant form (CRF47_BF) in Spain. AIDS Res Hum Retroviruses, 2010; 26,7:827–832.

14.

Berger

. HIV entry tropism. When one receptor is not enough. Adv Exp Med Biol, 1998; 452:151–157.

15.

Berger

, Murphy

, Farber

. Chemokine receptors as HIV coreceptors: Roles in viral entry, tropism, and disease. Annu Rev Immunol, 1999; 17:657–700.

16.

Connor

, Sheridan

, Ceradini

et al. Change in coreceptor use correlates with disease progression in HIV-1 infected individuals. J Exp Med, 1997; 185,4:621–628.

17.

Scarlatti

, Tresoldi

, Björndal

et al. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine, mediated suppression. Nat Med, 1997; 3,11:1259–1265.

18.

Huang

, Eshleman

, Toma

et al. Coreceptor tropism in human immunodeficiency virus type 1 subtype D: High prevalence of CXCR4 tropism and heterogeneous composition of viral populations. J Virol, 2007; 81,15:7885–7893.

19.

Cilliers

, Nhlapo

, Coetzer

et al. The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C. J Virol, 2003; 77,7:4449–4456.

20.

Ndung'u

, Sepako

, McLane

et al. HIV-1 subtype C in vitro growth and coreceptor utilization. Virology, 2006; 347,2:247–260.

21.

Pérez-Alvarez

, Muñoz

, Delgado

et al. Isolation and biological characterization of HIV-1 BG intersubtype recombinants and other genetic forms circulating in Galicia, Spain. J Med Virol, 2006; 78,12:1520–1528.

22.

Pérez-Alvarez

, Delgado

, Villahermosa

et al. Biological characteristics of newly described HIV-1 BG recombinants in Spanish individuals. AIDS, 2002; 16,4:669–672.

23.

Polonis

, de Souza

, Darden

et al. Human immunodeficiency virus type 1 primary isolate neutralization resistance is associated with the syncytium phenotype and lower CD4 cell counts in subtype CRF01_AE-infected patients. J Virol, 2003; 77,15:8570–8576.

24.

Cuevas

, Muñoz-Nieto

, Thomson

et al. HIV-1 transmission cluster with T215D revertant mutation among newly diagnosed patients from the Basque Country, Spain. J Acquir Immune Defic Syndr, 2009; 51,1:99–103.

25.

Cuevas

, Fernández-García

, Sánchez-García

et al. Incidence of non-B subtypes of HIV-1 in Galicia, Spain: High frequency and diversity of HIV-1 among men who have sex with men. EuroSurveill, 2009; 14,47:pii19413.

26.

Sullivan

, Hamouda

, Delpech

et al. Reemergence of the HIV epidemic among men who have sex with men in North America, Western Europe, and Australia, 1996–2005. Ann Epidemiol, 2009; 19,6:423–431.